LyrArc Article Gist
Pfizer's acquisition of Wyeth.

LyrArc Article Gist
How Cephalon's marketing strategy and tactics have caused the state attorney generals to investigate for abuses. This is useful information for other drug companies setting aggressive marketing goals, which might then lead to marketing the drug for more than its proper use and at higher dosages, or some other such abuse.

LyrArc Article Gist
See the related piece in BW

LyrArc Article Gist
The chief political reporter for the German daily The Bild, says Ursula Von der Leyen EU Commission president's performance on ensuring vaccine supplies is a disgrace for the EU and Germany. For once Brexiteers are proved right he says with having negotiated a better deal with vaccine suppliers, not being stingy like the EU officials, paying good money and securing supplies as early as April.  He says the EU's bureaucracy, its sluggish response, miserly attitude is now being confirmed in this health crisis and Germany is not looking good at all. Tiede says Leyen failed at the German Defense ministry and like other ministers in this situation was shifted into the EU Commission bureaucracy,only to fail again. He suggests Merkel and the heads of France, and Italy, Spain take over negotiating directly from now on with pharmaceutical companies. The EU officials are under severe criticism in Europe, shown here for different EU countries. Leyen is shown to have blundered further by creating a spat with Astra Zeneca- either she did not read the contract or was ignorant of what it meant, say critics. The EU's deal with Astra Zeneca was not with binding provisions, making EU officials at fault. Der Tiegesspiegel called EU's failure to admit its mistakes "jaw dropping" and bordered on "shamelessness." Der Spiegel calls it the worst catastrophe of Leyen's career. This now means Germany will have only 70% of its population vaccinated by September 2021, say experts. ...

LyrArc Article Gist
The drug industry which faces the prospect of losing billions of dollars in sales of epilepsy drugs if pharmacists substitute cheaper generics is using the Epilepsy Foundations state affiliates to lobby for legislatio which would make it harder for pharmacists to substitute generics for epilepsy. The FDA does not think generics are any different from the epilepsy drugs that will lose patent protection between 2008-2010.